<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01950234</url>
  </required_header>
  <id_info>
    <org_study_id>110271</org_study_id>
    <nct_id>NCT01950234</nct_id>
  </id_info>
  <brief_title>ACTH in Progressive Forms of MS</brief_title>
  <official_title>Treatment of Progressive Forms of Multiple Sclerosis With Pulsed ACTH (Acthar Gel)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, randomized, double-blind, placebo-controlled, multi-center study to&#xD;
      evaluate the safety, tolerability, and efficacy of adrenocorticotropic hormone (ACTH, Acthar&#xD;
      gel) administered as a pulsed regimen consisting of injections on three consecutive days per&#xD;
      month in patients with progressive forms of Multiple Sclerosis (MS). Patients will be&#xD;
      randomly assigned to either an ACTH arm or a placebo arm. The main hypotheses are that 1)&#xD;
      pulsed ACTH will be safe and well-tolerated, and 2) pulsed ACTH will slow progression of&#xD;
      clinical and paraclinical measures of MS progression compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients exhibiting a 20% worsening in T25FW at 36 months</measure>
    <time_frame>Month 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of ACTH</measure>
    <time_frame>Month 36</time_frame>
    <description>Safety and tolerability will be assessed via safety lab tests, skin and edema assessments, DEXA scans, symptom questionnaires and adverse event assessments.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Slowed progression of sustained cognitive disability</measure>
    <time_frame>Month 36</time_frame>
    <description>Brief Repeatable Battery of Neuropsychological Tests (BRB-N)</description>
  </other_outcome>
  <other_outcome>
    <measure>Retinal nerve fiber layer thickness</measure>
    <time_frame>Month 36</time_frame>
    <description>Decline in retinal nerve fiber layer thickness as measured by optical coherence tomography (OCT)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Secondary Progressive Multiple Sclerosis</condition>
  <condition>Primary Progressive Multiple Sclerosis</condition>
  <condition>Progressive Relapsing Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>ACTH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACTH administered subcutaneously as a pulsed regimen of 3 consecutive days per month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneous injections administered on 3 consecutive days per month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACTH</intervention_name>
    <description>Acthar gel</description>
    <arm_group_label>ACTH</arm_group_label>
    <other_name>Acthar gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients with a confirmed diagnosis of MS by McDonald criteria&#xD;
&#xD;
          -  Age &gt;/= 18 years&#xD;
&#xD;
          -  SPMS, PPMS, or PRMS phenotype, according to Lublin and Reingold criteria&#xD;
&#xD;
          -  EDSS 2.0 - 6.0, inclusive&#xD;
&#xD;
          -  Able to understand the consent process&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known intolerance of ACTH or corticosteroids&#xD;
&#xD;
          -  Diabetes mellitus, defined as pre-existing diagnosis, fasting blood glucose &gt; 125&#xD;
             mg/dl, or glycosylated hemoglobin &gt;/= 6.5%&#xD;
&#xD;
          -  Osteoporosis, defined as pre-existing diagnosis or T-score on dual-energy x-ray&#xD;
             absorptiometry (DEXA) scan of &lt;/= -2.5.&#xD;
&#xD;
          -  Current serious medical condition which may interfere with subject's ability to&#xD;
             complete the study, or for which pulsed ACTH therapy is contraindicated or might&#xD;
             complicate current therapy (e.g., cancer, severe psychiatric illness, chronic&#xD;
             infections, autoimmune disorders)&#xD;
&#xD;
          -  Treatment with cytotoxic agents (including but not necessarily limited to&#xD;
             mitoxantrone, cyclophosphamide, alemtuzumab, or rituximab) within 3 years prior to&#xD;
             randomization&#xD;
&#xD;
          -  Treatment with non-cytotoxic immunosuppressive agents (including but not necessarily&#xD;
             limited to corticosteroids, ACTH, azathioprine, mycophenolate mofetil, methotrexate or&#xD;
             natalizumab) within 3 months prior to randomization&#xD;
&#xD;
          -  Treatment with FDA-approved first-line MS disease-modifying therapies (B-interferon,&#xD;
             glatiramer acetate, fingolimod, teriflunomide or dimethyl fumarate) will be permitted,&#xD;
             as long as treatment has been ongoing and stable for at least 3 months prior to&#xD;
             randomization&#xD;
&#xD;
          -  Treatment with dalfampridine or compounded 4-aminopyridine (4-AP) will be permitted as&#xD;
             long as treatment has been ongoing and stable for at least 3 months prior to&#xD;
             randomization&#xD;
&#xD;
          -  Stimulant medications for fatigue (such as methylphenidate, modafinil, armodafinil,&#xD;
             amantadine or dextroamphetamine) will be permitted, but subjects will be asked to not&#xD;
             take these medications on study visit days until all study procedures/assessments are&#xD;
             completed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam F Carpenter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Neuroscience Research Unit, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Clinic Neuroscience</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wheaton Franciscan Healthcare - St Francis Center for Neurological Disorders</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 30, 2013</study_first_submitted>
  <study_first_submitted_qc>September 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2013</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

